SPARC.NSE · Sun Pharma Advanced Research Company Limited

-

Please sign in to comment on SPARC.NSE

1 Comment

Admin

5 years, 4 months ago

Sun Pharma Advanced Research Company Limited is currently in a long term uptrend where the price is trading 31.6% above its 200 day moving average.

From a valuation standpoint, the stock is 259.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 17.2.

Sun Pharma Advanced Research Company Limited's total revenue rose by 11.3% to $218M since the same quarter in the previous year.

Its net income has dropped by 21.8% to $-676M since the same quarter in the previous year.

Finally, its free cash flow grew by 89.2% to $-157M since the same quarter in the previous year.

Based on the above factors, Sun Pharma Advanced Research Company Limited gets an overall score of 3/5.

ABOUT

Sun Pharma Advanced Research Company Limited

Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications. The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma. Sun Pharma Advanced Research Company Limited was incorporated in 2006 and is based in Mumbai, India.

SPARC.NSE · Sun Pharma Advanced Research Company Limited

-

Sun Pharma Advanced Research Company Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Sun Pharma Advanced Research Company Limited using a moving average strategy